About

Copious research efforts have been undertaken in MS research in the last three decades to unravel immune mechanisms in the periphery thought to be responsible for disease onset and effector mechanisms mediating CNS damage.  However, the underlying molecular causes of MS are still not understood and prognostic estimates can hardly be given to patients in the absence of valid surrogate markers.  Traditional therapeutic disease modifying regimens aim at immunomodulation or immunosuppression and were developed in the context of autoimmune research in conjunction with other diseases such as rheumatoid arthritis, Crohn’s disease and diabetes mellitus.  However, response to anti-inflammatory therapeutic interventions differs significantly between MS and other autoimmune disorders.  Moreover, in many MS patients, response to the current interventions has only limited impact on disease progression.  Finally, novel therapies in MS aimed at reducing the CNS-directed immune responses are associated with a severe risk for opportunistic CNS infection.

There is currently an urgent need to go back to basics and apply completely novel ideas and unconventional methods as well as brand new technologies to research in this area.  Now is the time to take up the challenge and, for the first time in Germany, promote interaction between strong research groups at three different sites that all have the ideal prerequisites for illuminating and expanding highly novel and innovative perspectives in MS research.  The goal of this consortium, which consists of scientists from centers in the Rhine-Main area, Münster and Munich, is to unravel the pathology of MS and develop as well as understand novel therapeutic concepts.  The ideal prerequisites for such progress are provided by effectively linking scientists from neighboring disciplines with classical neuroimmunologists, who possess a proven track record in MS research and patient care and arise from an important and internationally visible nucleus in this field.  One key aspect here is the strong bidirectional crosstalk between pure experimental research in animal models and clinical research in human systems and patients, which allows the best transfer of basic knowledge into clinical care – and vice versa.

News

Mon, 20/09/2021
Register now: 1st Symposium inflammation and imaging
When?: from November 2nd to November 4th 2021 Where?: Schloss (seat of the University Administration) Muenster Organizers: Co-operative Research Centres 1009, 1450, Transregio 128, and Clinical Research Unit 342 – together with Interdisciplinary Centre of Clinical Research (IZKF) and Excellence Cluster Cells in Motion (CiM) Registration is open now! More information: here...more
Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more